Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction

Published on Jun 1, 2015in The American Journal of the Medical Sciences2.378
· DOI :10.1097/MAJ.0000000000000476
J. Zhang1
Estimated H-index: 1
 (Hebei Medical University)
Sources
Abstract
Abstract Objective This study was conducted to investigate the efficacy and safety of using a concurrent neoadjuvant chemoradiotherapy (a XELOX regimen) to treat adenocarcinoma of the gastroesophageal junction. Methods Seventy-six patients having resectable adenocarcinoma at the gastroesophageal junction (T3/4, N+, M0) were recruited to participate and randomly assigned to either a chemoradiotherapy group or a surgery group. Patients in the chemoradiotherapy group were orally given capecitabine (1,000mg/m 2 , twice daily for 14 days, days 1–14) and intravenous oxaliplatin (130mg/m 2 on day 1) for 2 cycles. Radiotherapy was performed with a total of 45Gy administered in 25 sessions for 5 weeks. Patients in the surgery group received only surgical intervention. Results In the concurrent chemoradiotherapy group, the overall response rate was 55.6% (20/36), tumor control rate was 100% and a pathological complete response was achieved in 16.7% (6/36). The entire chemoradiotherapy group had R0 resections as did 80% of the surgery group (32/40) ( P Conclusions Concurrent neoadjuvant chemoradiotherapy administration increased the rate of R0 resection and demonstrated favorable safety in patients with siewert ii or iii adenocarcinoma at the gastroesophageal junction. These results support the use of neoadjunctive chemoradiotherapy in the treatment of adenocarcinoma of the gastroesophageal junction.
References33
Newest
Feb 5, 2014·Radiation Oncology3.48
#1Francesco CelliniH-Index: 20
#2Alessio G. Morganti (UCSC: Catholic University of the Sacred Heart)H-Index: 35
Last. Vincenzo Valentini (UCSC: Catholic University of the Sacred Heart)H-Index: 68
view all 5 authors...
Gastroesophageal cancers (such as esophageal, gastric and gastroesophageal-junction -GEJ- lesions) are worldwide a leading cause of death being relatively rare but highly aggressive. In the past years, a clear shift in the location of upper gastrointestinal tract tumors has been recorded, both affecting the scientific research and the modern clinical practice. The integration of pre- or peri-operative multimodal approaches, as radiotherapy and chemotherapy (often combined), seems promising to fu...
Source
Jan 1, 2014·Annals of Surgical Oncology5.34
#1Takaki Yoshikawa (Kanagawa Prefectural Hospital)H-Index: 55
#2Kazuaki Tanabe (Hiroshima University)H-Index: 30
Last. Junichi Sakamoto (Nagoya University)H-Index: 56
view all 16 authors...
Background The prognosis for stage 3 gastric cancer is not satisfactory, even with S-1 adjuvant chemotherapy. A randomized phase II trial was conducted to compare two and four courses of neoadjuvant S-1/cisplatin (SC) and paclitaxel/cisplatin (PC) using a two-by-two factorial design for locally advanced gastric cancer. The primary endpoint was overall survival. We clarified the impact of these regimens on the secondary endpoints, including the clinical and pathological responses, chemotherapy-re...
Source
Oct 1, 2013·European Journal of Cancer9.16
#1Ulrich Ronellenfitsch (Heidelberg University)H-Index: 23
#2Matthias SchwarzbachH-Index: 28
Last. Katrin Jensen (Heidelberg University)H-Index: 24
view all 15 authors...
Background The prognosis of patients with gastroesophageal adenocarcinoma is poor. There is conflicting evidence regarding effects of preoperative chemotherapy on survival and other outcomes. Methods We conducted a meta-analysis with aggregate and individual patient data (IPD) to assess the effect of preoperative chemotherapy for gastroesophageal adenocarcinoma on survival and other outcomes. Two independent reviewers identified eligible randomised controlled trials (RCTs) comparing chemotherapy...
Source
Sep 1, 2013·Cancer Prevention Research3.49
#1Lee W. Jones (Duke University)H-Index: 96
#2Diane R. Fels (Duke University)H-Index: 8
Last. Mark W. Dewhirst (Duke University)H-Index: 134
view all 17 authors...
Aerobic exercise training (AET) is an effective adjunct therapy to attenuate the adverse side-effects of adjuvant chemotherapy in women with early breast cancer. Whether AET interacts with the antitumor efficacy of chemotherapy has received scant attention. We carried out a pilot study to explore the effects of AET in combination with neoadjuvant doxorubicin–cyclophosphamide (AC+AET), relative to AC alone, on: (i) host physiology [exercise capacity (VO2 peak), brachial artery flow-mediated dilat...
Source
Jan 1, 2013·Digestive Surgery2.59
#1Yukinori KurokawaH-Index: 52
#2Mitsuru SasakoH-Index: 78
Last. Yuichiro DokiH-Index: 93
view all 3 authors...
Esophagogastric junction (EGJ) adenocarcinomas are usually classified into one of the three categories of the Siewert system. The clinicopathological features of EGJ adenocarcinomas vary according to this classification scheme. The lymphatic flow in EGJ tumors of any type is mainly toward the abdomen, and nodal metastasis to the upper or middle mediastinum from Siewert type II or III tumors is relatively uncommon. Thus, the transhiatal approach is regarded as the standard in surgery for Siewert ...
Source
Jul 1, 2013·Yonsei Medical Journal2.76
#1Ji Yeong An (Yonsei University)H-Index: 35
#2Hyoung Il Kim (Yonsei University)H-Index: 34
Last. Sung Hoon Noh (Yonsei University)H-Index: 73
view all 6 authors...
response. The 1-, 2-, and 3-year disease-free survivals were 83.4%, 70%, and 52.2%. The 1-, 3-, 5-year overall survivals were 88.5%, 67.5%, and 51.2%, respectively. Although a complete pathologic response (ypT0N0M0) was achieved in 7 patients, 28.6% of them demonstrated recurrence of the tumor within 6 months after curative surgery. Conclusion: CCRTx rather than CTx appears to be more effective for achieving good pathologic response. Although favorable pathologic response has been achieved after...
Source
May 31, 2013·Journal of Ocular Pharmacology and Therapeutics2.67
#1Michele Iester (UniGe: University of Genoa)H-Index: 30
#2Serena Telani (UniGe: University of Genoa)H-Index: 5
Last. Daniela PaoliH-Index: 1
view all 8 authors...
Abstract Purpose: Supposedly, prostaglandin analogs (PGA) could reduce the central corneal thickness (CCT), while topical carbonic anhydrase inhibitors (TCAI) could increase CCT. The aim of the study was to evaluate clinically significant CCT effects in patients treated with PGA or TCAI. Methods: At least 50 glaucomatous patients were saved on the Italian Glaucoma Register from 16 different glaucoma centers. About 816 glaucomatous patients were found in the register; of these, 316 were recruited...
Source
Mar 1, 2013·Oncologist5.55
#1Michael S. Lee (Brigham and Women's Hospital)H-Index: 1
#2Harvey J. Mamon (Brigham and Women's Hospital)H-Index: 37
Last. Peter C. Enzinger (Harvard University)H-Index: 53
view all 15 authors...
Purpose. To determine the efficacy and toxicity of weekly neoadjuvant cetuximab combined with irinotecan, cisplatin, and radiation therapy in patients with locally advanced esophageal or gastroesophageal junction cancer.
Source
Feb 11, 2013·BMC Cancer4.43
#1Markus Moehler (University of Mainz)H-Index: 56
#2Ines Gockel (University of Mainz)H-Index: 45
Last. Heinz Schmidberger (University of Mainz)H-Index: 35
view all 13 authors...
Background This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric junction.
Source
Jan 4, 2013·Radiation Oncology3.48
#1Joseph M. Pepek (Duke University)H-Index: 6
#2Junzo Chino (Duke University)H-Index: 22
Last. Brian G. Czito (Duke University)H-Index: 31
view all 8 authors...
To examine toxicity and outcomes for patients treated with preoperative chemoradiotherapy (CRT) for gastric cancer. Patients with gastroesophageal (GE) junction (Siewert type II and III) or gastric adenocarcinoma who underwent neoadjuvant CRT followed by planned surgical resection at Duke University between 1987 and 2009 were reviewed. Overall survival (OS), local control (LC) and disease-free survival (DFS) were estimated using the Kaplan-Meier method. Toxicity was graded according to the Commo...
Source
1234
Cited By9
Newest
Nov 11, 2021·Frontiers in Oncology6.24
#1Yuan TianH-Index: 6
#2Jun WangH-Index: 171
Last. Dong WangH-Index: 1
view all 12 authors...
Source
Mar 17, 2021·BMC Surgery2.10
#1Jing Li (Hebei Medical University)H-Index: 3
#2Qun Zhao (Hebei Medical University)H-Index: 13
Last. Ming Liu (Hebei Medical University)H-Index: 1
view all 8 authors...
BACKGROUND To analyze whether neoadjuvant chemoradiotherapy (nCRT) could improve the survival for patients with adenocarcinoma of the esophagogastric junction compared with neoadjuvant chemotherapy (nCT). Both neoadjuvant chemotherapy alone and chemoradiotherapy before surgery have been shown to improve overall long-term survival for patients with adenocarcinoma in the esophagus or esophagogastric junction compared to surgery alone. It remains controversial whether nCRT is superior to nCT. METHO...
Source
Jan 1, 2021·American Journal of Translational Research4.06
#1Honghai Guo (Hebei Medical University)H-Index: 2
#2Yong Li (Hebei Medical University)H-Index: 10
Last. Peigang Yang (Hebei Medical University)H-Index: 6
view all 14 authors...
This study aimed to investigate the efficacy and safety of concurrent neoadjuvant chemoradiotherapy (CRT) plus apatinib in treating locally advanced, HER2-negative, Siewert's type II-III adenocarcinoma of esophagogastric junction (AEG) patients. Thirty eligible patients were analyzed in this single-arm, open-label, phase II trial. Patients received neoadjuvant regimen as follows: two cycles of apatinib (orally, 250 mg/day on day 1-28), two cycles of capecitabine (orally, 1,000 mg/m2 twice daily ...
ABSTRACT Purpose Limited guidance exists regarding the relative effectiveness of treatment options for non-metastatic, operable patients with adenocarcinoma of the esophagus or gastroesophageal junction (GEJ). In this systematic review, the American Radium Society (ARS) gastrointestinal expert panel convened to develop Appropriate Use Criteria (AUC) evaluating how neoadjuvant and/or adjuvant treatment regimens compared to each other, surgery alone, or definitive chemoradiation in terms of respon...
Source
Jun 22, 2020·Journal of Clinical Oncology44.54
#1Manish A. Shah (Cornell University)H-Index: 74
#2Erin B. Kennedy (American Society of Clinical Oncology)H-Index: 20
Last. Wayne L. Hofstetter (University of Texas MD Anderson Cancer Center)H-Index: 77
view all 12 authors...
PURPOSETo develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with locally advanced esophageal cancer.METHODSASCO convened an Expert Panel to co...
Source
Jun 1, 2019·Journal of gastrointestinal oncology2.89
#1Steven EngelH-Index: 2
#2Adam Awerbuch (UM: University of Miami)H-Index: 3
Last. Lorraine PortelanceH-Index: 22
view all 7 authors...
Background: This is the first meta-analysis to study optimal radiation dose in the setting of concurrent neoadjuvant chemoradiotherapy (cnCRT) for esophageal cancer (EC). We sought to compare outcomes between high dose radiotherapy (HDRT) [>48.85 Gy biologically effective dose (BED)] group and low dose radiotherapy (LDRT) (≤48.85 Gy BED) for patients with EC receiving cnCRT. Methods: Medline, Embase, and Cochrane databases were searched independently by two members of our team on August 07, 2017...
Source
Jan 1, 2019·Journal of Cancer4.21
#3Yan Zhao (PRC: China Medical University (PRC))H-Index: 8
Background: Neoadjuvant chemoradiation (CRT) remains controversial in the treatment of the oesophagus or gastro-oesophageal junction (GOJ) carcinomas. Methods: We conducted a meta-analysis to assess the efficacy and safety of Neoadjuvant CRT plus surgery comparing with neoadjuvant CT plus surgery or surgery alone. Feasible studies were searched from electronic databases. The outcomes of survival, R0 resection rate and adverse effects were analyzed. The outcomes were measured with relative risk (...
Source
Oct 1, 2018·Nutrition and Cancer2.36
#1Qun Zhao (Hebei Medical University)H-Index: 13
#2Yong Li (Hebei Medical University)H-Index: 8
Last. Yuan Tian (Hebei Medical University)H-Index: 6
view all 7 authors...
AbstractObjective: To study the effects of preoperative enteral nutrition (EN) on postoperative recent nutritional status (PRNS) in patients with Siewert II and III adenocarcinomas of esophagogastric junction (AEG) after neoadjuvant chemoradiotherapy (NCRT).Methods: A total of 66 patients with resectable AEG (Siewert II and III) were randomly divided into two groups. The trial group accepted oral nutrition supplementation (ONS) for 7 days before surgery while the control not.Results: Nutrition i...
Source
Jan 9, 2018·Ejso4.42
#1Xueke Ge (Hebei Medical University)H-Index: 1
#2Qun Zhao (Hebei Medical University)H-Index: 1
Last. Xueying Qiao (Hebei Medical University)H-Index: 3
view all 7 authors...
Abstract Purpose Preoperative therapy improves overall survival (OS) after surgery in patients with adenocarcinoma of the esophagogastric junction (AEG). We aimed to retrospectively analyze whether preoperative chemoradiotherapy (CRT) could improve the prognosis of patients with locally advanced Siewert II and III AEG comparing with preoperative chemotherapy alone (CT). Patients and methods From March 2012 to December 2015, 170 patients with locally advanced (cT3-4NxM0) Siewert II and III AEG we...
Source
#1Xingchu Ni (Nanjing Medical University)
#2Kun (Kim) Huang (BU: Boston University)
Neoadjuvant radiation therapy or chemoradiotherapy followed by surgery has the potential to improve patient survival by reducing the risk of locoregional and distant metastasis of gastric cardiac cancer in both thoracic and abdominal organs. Because of the limited case number in prior clinical trials on the efficacy of radiation or chemoradiotherapy for gastric cardiac cancer, multicenter studies with large case numbers are urgently needed to establish an optimal therapy protocol for this cancer...
Source
12
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.